This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 6 for:    Cerebral EDV
Previous Study | Return to List | Next Study

A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM) (CerebralEDV)

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2017 by Engeneic Pty Limited
Sponsor:
Collaborator:
Johns Hopkins University
Information provided by (Responsible Party):
Engeneic Pty Limited
ClinicalTrials.gov Identifier:
NCT02766699
First received: May 3, 2016
Last updated: June 1, 2017
Last verified: June 2017
  Purpose
The purpose of the Cerebral EDV study is to determine the safety and tolerability of EGFR(V)-EDV-Dox in order to establish the best dose level to be used in future studies. The study will also examine the body's immune response to EGFR(V)-EDV-Dox and assess if it is effective in the treatment of patients with recurrent glioblastoma multiforme (GBM).

Condition Intervention Phase
Glioblastoma Astrocytoma, Grade IV Drug: EGFR(V)-EDV-Dox Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of EGFR (Vectibix® Sequence)-Targeted EnGeneIC Dream Vectors Containing Doxorubicin (EGFR(V)-EDV-Dox) in Subjects With Recurrent Glioblastoma Multiforme (GBM)

Resource links provided by NLM:


Further study details as provided by Engeneic Pty Limited:

Primary Outcome Measures:
  • Safety outcome measures: Adverse Events (AE's) graded according to CTCAE V.4.3, physical/neurologic examination, Karnofsky Performance Status (KPS), vital signs, echocardiogram, ECG, hematology, serum chemistry & urinalysis. [ Time Frame: Safety measures will be conducted from Study Day 1 as per study schedule to safety follow-up visit 30 (+5 days) post last dose. ]

Secondary Outcome Measures:
  • Efficacy outcome measure: Disease response will be measured by Magnetic Resonance Imaging (MRI) using Response Assessment in Neuro-Oncology (RANO). [ Time Frame: Screening, then post cycle (Days 50-56) ]
  • Identification of a recommended Phase 2 dose (RP2D) of EGFR(V)-EDV-Dox in subjects with recurrent GBM : Dose limiting toxicity (DLT) evaluable subjects. [ Time Frame: DLT evaluable subjects are those who experience a DLT during the evaluation period, between days 1-28. In subjects with an elevated interleukin-6 (IL-6) the DLT evaluation period is days 1-42 for 5 x 10^9 and days 1-49 for 8 x 10^9. ]
  • Overall survival outcome measure. [ Time Frame: The number of days from the date of first administration of EGFR(V)-EDV-Dox to the date of death, regardless of cause up to 60 months. ]

Estimated Enrollment: 20
Actual Study Start Date: October 25, 2016
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: February 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: EGFR(V)-EDV-Dox
EGFR(V)-EDV-Dox administered via 20 minute intravenous infusion once a week for seven weeks (1 Cycle). Subjects will receive one of two dose levels: 5 x 10^9 or 8 x 10^9. Subjects may receive further cycles of treatment if the tumor remains stable or is responding, and/or they are deriving clinical benefit from the therapy and are tolerating treatment.
Drug: EGFR(V)-EDV-Dox
EGFR(V)-EDV-Dox using EnGeneIC EDV™ technology is a bacterially derived minicell which packages a toxic payload, Doxorubicin, into a 400 nm particle which targets specific cancer cells using bispecific antibodies (BsAb). BsAb-targeted, payload-packaged EDV nanocells only exit the leaky blood vessels associated with tumors and enter into the tumor microenvironment. The BsAb binds to the tumor cell-surface receptor, where the EDV is taken up, broken down within the cancer cell and releases the Doxorubicin. The residual EDVs that do not make it into the tumor microenvironment, are engulfed by cells of the immune system and since the EDVs are derived from bacteria, they carry potent immuno-stimulating components which appear to bypass the immuno-suppression caused by the tumor.
Other Names:
  • EnGeneIC Dream Vector™
  • EnGeneIC Delivery Vehicle™

Detailed Description:

This is an open-label, Phase 1, dose exploration and preliminary immunogenicity study of single agent EGFR(V)-EDV-Dox in subjects with recurrent glioblastoma (GBM). Eligible subjects enrolled in the study will receive EGFR(V)-EDV-Dox administered weekly for 7 weeks via IV 20 minute infusion, followed by radiological evaluation at week 8 (1 Cycle). Subjects may continue to receive subsequent cycles of EGFR(V)-EDV-Dox unless the subject becomes intolerant to investigational product (IP), withdraw consent or the individual is no longer receiving clinical benefit (factors taken in to consideration will be disease progression radiologically or clinically, and clinical benefits to quality of life). Tumour assessment will be repeated after each 7 week cycle (week 8).

The study will take place in two parts, Part 1 (Dose Exploration) and Part 2 (Dose Expansion).

Part 1 - Dose Exploration will assess the safety and tolerability of multiple doses of drug at two dose levels (5 x 10^9 and 8 x 10^9) and will enroll prior to Part 2. Three subjects will be recruited per dose level. Enrollment will begin with the 5 x 10^9 dose level, and the decision to enroll to the 8 x 10^9 dose level will follow a comprehensive safety evaluation and a standard 3 + 3 dose escalation study design.

Part 2 - Dose Expansion will be conducted pending safety results of Part 1 to provide guidance regarding the recommended phase 2 dose (RP2D). Subjects will be treated and assessed as outlined in Part 1 above. If 0 out of 3 subjects, or 1 out of 6 subjects, experience dose limiting toxicities (DLTs) at the 5 x 10^9 dose level in Part 1, additional subjects to a total of 10 will be recruited to this dose level in Part 2. Similarly, if 0 out of 3 subjects, or 1 out of 6 subjects, experience DLTs at the 8 x 10^9 dose level in Part 1, additional subjects to a total of 10 will be recruited to this dose level in Part 2. If both dose levels are tolerated, a total of 10 subjects per dose level will be enrolled.

A safety follow-up visit must be performed 30 (+5) days after the last dose of drug for all subjects.All subjects who discontinue investigational product and who have not withdrawn full consent to participate in the study will continue in the long term follow-up phase. Long term follow-up will continue approximately every 1 month for 12 months, from the 30 (+5) day follow-up visit, then approximately every 2-3 months for the extent of subject survival.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Karnofsky Performance Status (KPS) ≥ 60%.
  2. Life expectancy ≥ 3 months.
  3. Pathologically documented, and definitively diagnosed recurrent World Health Organization (WHO) Grade IV astrocytoma (GBM).
  4. Participant must have archived tumor tissue available from initial diagnosis or subsequent relapse(s) of Grade IV GBM for submission for central review at Investigational sites local laboratories.
  5. Recurrence or progression of disease (confirmed by MRI and measurable by RANO criteria) following receipt of standard of care therapy, which includes maximum safe surgical resection, standard adjuvant radiation/temozolomide and maintenance temozolomide treatment.
  6. Participant has received ≤ 1 other chemotherapy regimen other than temozolomide (ie, carboplatin, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), Lomustine (CCNU), etc).
  7. Participant may be receiving steroid therapy at time of enrollment (stable dose of ≤ 4 mg/day of dexamethasone or steroid equivalent).
  8. Ability to undergo MRI evaluation.
  9. Participant has ≥ 1 site of bi-dimensionally measurable disease measured using contrast enhanced MRI.
  10. Hematological function:

    • White blood cell count (WBC) ≥ 3.0 x 109/L
    • Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
    • Platelet count ≥ 100 x 109/L
    • Hemoglobin > 9 g/dL
    • Prothrombin time (PT) or partial thromboplastin time (PTT) < 1.5 x upper limit of normal (ULN)
    • International normalized ratio (INR) < 1.5 x ULN
  11. Renal function:

    • Blood urea nitrogen (BUN) < 30 mg/dL
    • Creatinine serum levels ≤ 1.5 x ULN
    • Or creatinine clearance ≥ 60 mL/minute for subjects with serum creatinine outside the normal range (calculated using the Cockcroft-Gault equation).
  12. Hepatic function:

    • Aspartate aminotransferase (AST) < 2.5 x ULN (3 x ULN for subjects on chronic anticonvulsive therapies known to increase transaminases).
    • Alanine aminotransferase (ALT) < 2.5 x ULN (3 x ULN for subjects on chronic anticonvulsive therapies known to increase transaminases).
    • Alkaline phosphatase (ALP) < 2.5 x ULN (3 x ULN for subjects on chronic anticonvulsive therapies).
    • Total bilirubin ≤ 1 x ULN (unless elevated due to Gilbert's syndrome or extrahepatic source as denoted by increased indirect bilirubin fraction. Subjects with ≥1 x ULN will be tested for direct bilirubin fraction so that the indirect fraction can be calculated).
  13. Adequate cardiac function with left ventricular ejection fraction (LVEF) ≥ 55% at baseline.
  14. Serum phosphate levels that are within normal limits (2.4 - 4.1 milligrams per deciliter mg/dL) at baseline.
  15. Subject meets the reproductive criteria as follows:

    • Female subjects who are of non-reproductive potential (ie, post menopausal by history - no menses for ≥ 1 year and follicle-stimulating hormone (FSH) level consistent with post-menopausal status; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy).
    • Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days prior to the 1st dose, if more than 7 days prior, a urine pregnancy test must be performed before the 1st dose. The female subject must be willing to use highly effective methods of birth control during the period of therapy and for 6 months following the last study IP administration. Highly effective methods of birth control include sexual abstinence, hormonal birth control, or intrauterine device (women), vasectomy or a condom with spermicide (men) in combination with barrier methods.
    • Male subjects who are willing to use highly effective methods of birth control during the period of therapy and for 6 months following the last IP administration.
    • All study subjects must be willing to ensure that corresponding sexual partners practice these same methods of highly effective birth control for the same duration.

Exclusion Criteria:

  1. History of central nervous system bleeding as defined by stroke or intraocular bleed within 6 months of enrollment.
  2. Evidence of acute intracranial / intra-tumoral hemorrhage, except for participants with stable grade 1 hemorrhage.
  3. History of coronary artery disease, with or without angina pectoris or myocardial infarction, symptomatic congestive heart failure (New York Heart Association > Class II), uncontrolled hypertension (systolic > 160 mmHg or diastolic > 100 mmHg) or cardiac arrhythmias requiring anti-arrrhythmic therapy.
  4. Clinically significant electrocardiogram (ECG) changes at enrollment which obscure the ability to assess the PR, QT, and QRS interval; congenital long QT syndrome.
  5. Active infection requiring treatment.
  6. History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer, or other solid tumors curatively treated with no evidence of disease for ≥ 2 years.
  7. Known positive test for human immunodeficiency virus infection (HIV), or active hepatitis B or hepatitis C infection.
  8. Receipt of therapies or procedures prior to first dose including:

    • Radiation therapy (within 12 weeks of Study Day 1 or has not recovered from the toxic effects of such therapy).
    • Bevacizumab® or other anti-angiogenic therapy.
    • Gliadel® Wafer (within 6 months of Study Day 1, or has not recovered from the toxic effects of such therapy).
    • Immunotherapeutic agents, vaccines, or monoclonal antibody therapy (within 4 weeks of Study Day 1 or has not recovered from the toxic effects of such cancer therapy).
    • Temozolomide or other chemotherapy (within 4 weeks of Study Day 1 or 6 weeks for nitrogen mustards, or has not recovered from the toxic effects of such cancer therapy).
    • Anticoagulation therapy (within 7 days of Study Day 1), except low molecular weight heparins or low dose aspirin.
    • Other investigational therapy (within 30 days of Study Day 1).
    • Medications known to cause QTc interval prolongation (within 7 days OR five half-lives prior to Study Day 1, whichever is longer).
    • Surgical resection of brain tumor (within 4 weeks of Study Day 1 or has not recovered from acute side effects of such therapy except for neurological effects).
    • Any major surgery (within 4 weeks of Study Day 1, or has not recovered from the effects of such surgery).
  9. Subject has a known allergic/hypersensitivity to investigational components or excipients (doxorubicin, trehalose, monoclonal antibody therapy, penicillin class of antibiotics, gentamicin (or other aminoglycosides), or ciprofloxacin hydrochloride (or other quinolones)).
  10. Evidence of anti-Salmonella Lipopolysaccharide (LPS) antibodies at screening.
  11. If female, is pregnant or is breast feeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02766699

Contacts
Contact: Kelly Szajna, RN BSN 410-502-4081 kszajna1@jhmi.edu
Contact: Jessica Wollett, MA 410-502-7752 jwollet1@jhmi.edu

Locations
United States, Maryland
John Hopkins Hospital Recruiting
Baltimore, Maryland, United States, 21287
Contact: Gary Gallia, MD PhD    410-614-0585    ggallia1@jhmi.edu   
Contact: Kelly Szajna, RN BS    4105024081    kszajna1@jhmi.edu   
Principal Investigator: Gary L Gallia, MD PhD         
Principal Investigator: Stuart A Grossman, MD         
United States, New York
Lenox Hill Hospital, Northwell Health Recruiting
New York, New York, United States, 10075
Contact: Tamika Wong, MPH    212-434-4836    twong4@northwell.edu   
Principal Investigator: John A Boockvar, MD         
Sponsors and Collaborators
Engeneic Pty Limited
Johns Hopkins University
Investigators
Study Director: Jennifer MacDiarmid, Ph.D Engeneic Pty Limited
Study Director: Himanshu Brahmbhatt, Ph. D Engeneic Pty Limited
Principal Investigator: Gary L Gallia, M.D., Ph.D Johns Hopkins University
Principal Investigator: Stuart A Grossman, M.D. Johns Hopkins University
  More Information

Responsible Party: Engeneic Pty Limited
ClinicalTrials.gov Identifier: NCT02766699     History of Changes
Other Study ID Numbers: ENG7
Study First Received: May 3, 2016
Last Updated: June 1, 2017
Individual Participant Data  
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Engeneic Pty Limited:
Brain Neoplasms
Astrocytoma, Grade IV
Doxorubicin
Glioblastoma
Neoplasms
Neoplasms by Site
Antineoplastic Agents
Drug Delivery Systems
Molecular Targeted Therapy
Nanoparticles
Disease Progression
Recurrence
Immunotherapy
Receptor, Epidermal Growth Factor
Antibodies, Bispecific

Additional relevant MeSH terms:
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Doxorubicin
Liposomal doxorubicin
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 23, 2017